PROJECT
Our values are equity, solidarity, sustainability and innovation.
Overview
HORUS involves the first longitudinal cohort of European SOT recipients. In a sub-‘HORUS-exploratory cohort’, we will perform a thorough investigation of viral, clinical and immunological characteristics.
Combining those parameters will provide a signature early after transplantation to predict the risk of developing CMV infection and a signature at Day 0 of infection to predict the risk of CMV disease severity.
This signature will then be validated retrospectively by the whole cohort and prospectively in a ‘proof-of-concept’ study. Moreover, HORUS will include functional in vitro and mouse models to investigate the mechanisms of lymphocyte response to CMV and provide innovative methods to increase CMV-specific immunity.
Altogether, HORUS will enhance personalised clinical prevention and the treatment of CMV disease, ultimately improving patient outcomes.
